Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ard.2025.05.013 | DOI Listing |
Publication Analysis
Top Keywords
corrigendum bimekizumab
4
bimekizumab treatment
4
treatment biologic
4
biologic dmard-naïve
4
dmard-naïve patients
4
patients active
4
active psoriatic
4
psoriatic arthritis
4
arthritis 52-week
4
52-week efficacy
4
Similar Publications
Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414.
Ann Rheum Dis
June 2025
Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, The Netherlands; Zuyderland Medical Centre, Heerlen, The Netherlands.